Gain Therapeutics, Inc. Share Price & Technical Analysis
GANX · $1.78 (+1.71%)
Healthcare / Biotechnology
$1.78
+1.71%
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and tr…
Price chart
Seasonality
May has 0 positive and 4 negative years (last 5 years shown)
0% return in May, -14% avg return in past 3 year May month.
-33% return in 2026, 31% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -45% | 44% | -27% | -5% | 0% | – | – | – | – | – | – | – | -33% |
| 25 | -5% | 0% | -10% | 5% | -14% | 0% | -17% | 33% | -10% | 11% | 75% | -9% | 61% |
| 24 | 18% | 15% | -17% | -27% | -17% | -50% | -15% | 0% | 64% | 39% | -24% | 22% | 7% |
| 23 | 25% | 5% | 14% | 2% | -10% | -4% | -9% | -13% | -6% | -12% | -25% | 57% | 24% |
| 22 | -26% | -10% | 8% | -19% | -12% | 24% | 14% | -12% | -3% | 3% | -12% | 3% | -41% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$75.71M
P/E ratio
—
52W high
$4.34
52W low
$1.41
Volume
4,12,423
Beta
0.15
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Gain Therapeutics, Inc. share price today?
- Gain Therapeutics, Inc. (GANX) last traded around $1.78 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GANX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GANX. Download the app for real-time alerts.
- How can I analyze Gain Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.